Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

SNDX

Live52w high -22.1%

Annual Quarterly

Core line items from SNDX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Syndax Pharmaceuticals, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$81.26M	$64.86M	$172.35M	$103.62M	$57.75M
Operating Income	Not available	$-34.20M	$-273.08M	$-210.54M	$-153.11M
Net Income	Not available	$-42.67M	$-285.42M	$-217.41M	$-71.85M
EPS (Diluted)	$-0.49	$-0.48	$-3.29	$-2.51	$-1.82
Total Assets	Not available	$472.67M	$529.71M	$551.79M	$596.15M
Total Liabilities	Not available	$431.05M	$465.08M	$436.36M	$438.73M
Cash & Equivalents	Not available	$130.89M	$134.93M	$116.81M	$108.64M
Free Cash Flow OCF − CapEx	Not available	Not available	$-323.17M	Not available	Not available
Shares Outstanding	Not available	88.54M	87.41M	86.91M	86.06M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from SNDX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -22.1%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Syndax Pharmaceuticals, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$81.26M	$64.86M	$172.35M	$103.62M	$57.75M
Operating Income	Not available	$-34.20M	$-273.08M	$-210.54M	$-153.11M
Net Income	Not available	$-42.67M	$-285.42M	$-217.41M	$-71.85M
EPS (Diluted)	$-0.49	$-0.48	$-3.29	$-2.51	$-1.82
Total Assets	Not available	$472.67M	$529.71M	$551.79M	$596.15M
Total Liabilities	Not available	$431.05M	$465.08M	$436.36M	$438.73M
Cash & Equivalents	Not available	$130.89M	$134.93M	$116.81M	$108.64M
Free Cash Flow OCF − CapEx	Not available	Not available	$-323.17M	Not available	Not available
Shares Outstanding	Not available	88.54M	87.41M	86.91M	86.06M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.